The Etiopathogenesis of Autoimmunity

ABSTRACT

Acquisition by mammals of an adaptive immune system was an evolutionary leap, but occurred at the cost of autoimmunity. The necessity for self-recognition was appreciated in 1900, but autoimmune disease did not become a clinical reality until the 1950s-still the perimeters are indistinct. Autoimmune responses recapitulate the complex events of normal immune responses but cannot shut down. Immune tolerance is established during repertoire development centrally in thymus or bone marrow by deletion of self-reactive immunocytes, and is supplemented peripherally by regulatory T cells (Tregs). A startling discovery is the autoimmune regulator AIRE gene that enables expression of organ-specific autoantigens for intrathymic deletional tolerance of T cells. The origins, activities, and markers of Tregs are under intensive investigation. Of genes implicated in autoimmune, only few are characterized; contributions of environment are similarly uncertain. Time-latency considerations implicate stochastic factors or chance in the etiopathogenesis of autoimmunity, whether they are somatic mutations or successive random gene-environment interactions. Solutions to etiopathogenesis require novel experimental models and finely designed gene-environment studies on human populations. Perhaps immunomodulatory therapies will effect cures before causes are fully understood.

KEYWORDS

Autoimmunity - immune response - immune tolerance - gene-environment interaction - somatic mutation

REFERENCES

• 1 Klein J, Nikolaidis N. The descent of the antibody-based immune system by gradual evolution.  Proc Natl Acad Sci U S A. 2005;  102 169-174
• 2 Mackay I R. The “Autoimmune diseases” 40th anniversary.  Autoimmun Rev. 2002;  1 5-11
• 3 Mackay I R. Roots and routes to autoimmunity. In: Immunology-The Making of a Modern Science London; Academic Press 1995: 49-62
• 4 Burnet F M. The immunological significance of the thymus. An extension of the clonal theory of immunity.  Aust Ann Med. 1962;  11 79-91
• 5 Bielschowsky M, Helyer B J, Howie J B. Spontaneous haemolytic anaemia in mice of the NZB/BL strain.  Proc Univ Otago Med Sch. 1959;  37 9-11
• 6 Makino S, Kunimoto K, Muraoka Y et al.. Breeding of a non-obese, diabetic strain of mice.  Exp Anim. 1980;  29 1-13
• 7 Rose N R, Mackay I R. Prelude. In: Rose NR, Mackay IR The Autoimmune Diseases, 3rd ed. San Diego, CA; Academic Press 1998: 1-4
• 8 Hansson G K. Inflammation, atherosclerosis and coronary artery disease.  N Engl J Med. 2005;  352 1685-1695
• 9 MacDonald T T, Monteleone G. Immunity, inflammation, and allergy in the gut.  Science. 2005;  307 1920-1925
• 10 Sollid M. Molecular basis of celiac disease.  Annu Rev Immunol. 2000;  18 53-81
• 11 Mackay I R. Hepatic disease and systemic lupus erythematosus. Coincidence or convergence. In: Lahita RG Systemic Lupus Erythematosus, 4th ed. San Diego, CA; Elsevier Science 2004: 993-1017
• 12 Kinoshita H, Omagari K, Whittingham S et al.. Autoimmune cholangitis and primary biliary cirrhosis-an autoimmune enigma.  Liver. 1999;  19 122-128
• 13 Alsen P S, Davis K L. Inflammatory response in Alzheimer’s disease: implications for therapy.  Am J Psychiatry. 1994;  151 1105-1113
• 14 Lazaridis K N, La Russo N F. Examining the increased IgM production and ursodeoxycholic acid treatment in PBC.  Gastroenterology. 2005;  128 498-500
• 15 Tolstoy L. Anna Karenina. Translated by Townsend RS. Geneva; Edito-Service S.A. 1887
• 16 Casciola-Rosen L, Andrade F, Ulanet D et al.. Cleavage by granzyme B is strongly predictive of autoantigen status: Implications for initiation of autoimmunity.  J Exp Med. 1999;  190 815-825
• 17 Höglund P, Mintern J, Waltzinger C et al.. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell autoantigens in the pancreatic lymph nodes.  J Exp Med. 1999;  189 331-339
• 18 Scheinecker C, McHugh R, Shevach E M, Germain R N. Constitutive presentation of a natural tissue autoantibody exclusively by dendritic cells in the draining lymph node.  J Exp Med. 2002;  196 1079-1090
• 19 Vinuesa C G, Tangye S G, Moser B, Mackay C R. T follicular helper cells, and their role in T dependent antibody responses and autoimmunity.  Nat Rev Immunol. 2005;  , In press
• 20 Kuppers R, Klein U, Hansmann M L, Rajewsky K. Cellular origin of human B-cell lymphomas.  N Engl J Med. 1999;  341 1520-1529
• 21 Mackay C R. Immunological memory.  Adv Immunol. 1993;  53 217-265
• 22 Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation.  Science. 1996;  272 54-60
• 23 Zinkernagel R M. On differences between immunity and immunological memory.  Curr Opin Immunol. 2002;  14 523-536
• 24 Seder R A, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation.  Nat Immunol. 2003;  4 835-842
• 25 Holmes S, He M, Xu T, Lee P L. Memory T cells have gene expression patterns intermediate between naïve and effector.  Proc Natl Acad Sci U S A. 2005;  102 5519-5523
• 26 Mackay I R, Burnet F M. Autoimmune diseases. In: Kugelmass IN Springfield; 1963
• 27 Serreze D V, Fleming S A, Chapman H D et al.. B lymphocytes are critical antigen presenting cells for the initiation of T-cell mediated autoimmune diabetes in nonobese diabetic mice.  J Immunol. 1998;  161 3912-3918
• 28 Monach P A, Benoist C, Mathis D. The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease.  Adv Immunol. 2004;  82 217-248
• 29 Amiramahdi S F, Whittingham S, Crombie D E et al.. Arthritogenic anti-type II collagen antibodies are pathogenic for cartilage-derived chondrocytes independent of inflammatory cells.  Arthritis Rheum. 2005;  52 1897-1906
• 30 Ruiz-Arguelles A, Rivadeneyra-Espinoza L, Alarcon-Segovia D. Antibody penetration into living cells: pathogenic, preventive and immunotherapeutic implications.  Curr Pharm Des. 2003;  9 1881-1887
• 31 Cope A P, Feldmann M. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease.  Curr Opin Immunol. 2004;  16 780-786
• 32 Kazatchkine M D, Kaveri S V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.  N Engl J Med. 2001;  345 747-755
• 33 Goldstein G, Mackay I R. The Human Thymus. London; William Heineman 1969
• 34 Whittingham S, Mackay I R. The ‘pemphigus’ antibody and immunopathies affecting the thymus.  Br J Dermatol. 1971;  84 1-6
• 35 Cohen I R. The cognitive paradigm and the immunological homunculus.  Immunol Today. 1992;  13 490-494
• 36 Anderson M S, Venanzi E S, Klein L et al.. Projection of an immunological self shadow within the thymus by the aire protein.  Science. 2002;  298 1395-1401
• 37 Kuroda N, Mitani T, Takeda N et al.. Development of autoimmunity against unrepressed target antigen in the thymus of aire-deficient mice.  J Immunol. 2005;  174 1862-1870
• 38 Grimalde C M, Hicks R, Diamond B. B cell selection and susceptibility to autoimmunity.  J Immunol. 2005;  174 1775-1781
• 39 Verkoczy L K, Martensson A S, Nemazee D. The scope of receptor editing and its association with autoimmunity.  Curr Opin Immunol. 2004;  16 808-814
• 40 Rice J S, Newman J, Wang C et al.. Receptor editing in peripheral B cell tolerance.  Proc Natl Acad Sci USA. 2005;  102 1608-1613
• 41 Ohashi P S, Oehen S, Buerki K et al.. Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice.  Cell. 1991;  65 305-317
• 42 Mackay F, Browning J L. BAFF: a fundamental survival factor for B cells.  Nat Rev Immunol. 2002;  2 465-475
• 43 Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells.  Adv Immunol. 2003;  81 331-371
• 44 Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation.  J Clin Invest. 2004;  114 1198-1208
• 45 Roberts W K, Darnell R B. Neuroimmunology of the paraneoplastic neurological degenerations.  Curr Opin Immunol. 2004;  16 616-622
• 46 Mackay I R. Science, medicine and the future. Tolerance and autoimmunity.  BMJ. 2000;  321 93-96
• 47 Invernizzi P, Selmi C, Mackay I R et al.. From bases to basis: linking genetics to causation in primary biliary cirrhosis.  Clin Gastroenterol Hepatol. 2005;  3 401-410
• 48 Gillespie K M, Bain S C, Barnett A H et al.. The rising incidence of type 1 diabetes and reduced contribution of high-risk HLA haplotypes.  Lancet. 2005;  364 1699-1700
• 49 Pugliese A, Gianani R, Moromisato R et al.. HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM.  Diabetes. 1995;  44 608-613
• 50 Outschoorn I M, Rose N R, Burek C L et al.. Heritability of levels of autoantibodies using the method of plotting regression of offspring on midparent (ROMP).  Autoimmunity. 2005;  34 325-326
• 51 Arbuckle M R, McClain M T, Rubertone M V et al.. Development of autoantibodies before the clinical onset of systemic lupus erythematosus.  N Engl J Med. 2003;  349 1526-1533
• 52 Tuomilehto J, Zimmet P, Mackay I R et al.. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease.  Lancet. 1994;  343 1383-1385
• 53 Metcalf J V, Bhopal R S, Gray J et al.. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England.  Int J Epidemiol. 1997;  26 830-836
• 54 Trudeau J D, Dutz J P, Arany E et al.. Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes?.  Diabetes. 2000;  49 1-7
• 55 Selmi C, Balkwill D L, Invernizzi P et al.. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium.  Hepatology. 2003;  38 1250-1257
• 56 Wekerle H, Hohlfeld R. Molecular memory in multiple sclerosis.  N Engl J Med. 2003;  349 185-186
• 57 Davies J M. Multiauthor review: molecular mimicry.  Cell Mol Life Sci. 2000;  57 523-578
• 58 Nitz N, Gomes C, de Cassia Rosa A et al.. Heritable integration of kDNA minicircle sequences from Trypanosoma cruzi into the avian genome: insights into human Chagas disease.  Cell. 2004;  118 175-186
• 59 Long S A, Quan C, Van de Water J et al.. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis.  J Immunol. 2001;  167 2956-2963
• 60 Coggon D IW, Martyn C N. Time and chance: the stochastic nature of disease causation.  Lancet. 2005;  365 1434-1437
• 61 Puck J M. Somatic mutations-not just for cancer anymore.  N Engl J Med. 2004;  351 1388-1390
• 62 Burch P JR. An enquiry concerning growth, disease and aging. Edinburgh, United Kingdom; Oliver and Boyd 1968
• 63 Burnet F M. Autoimmunity and Autoimmune Disease, Chapter 10. Lancaster, United Kingdom; Medical and Technical Publishing 1972
• 64 Fischer A, Rieux-Laucat F, Le Deist F. Autoimmune lymphoproliferative syndromes (ALPS): models for the study of peripheral tolerance.  Rev Immunogenet. 2000;  2 52-60
• 65 Sakaguchi S. Naturally arising CD4⁺ regulatory T cells for immunologic self-tolerance and negative control of immune responses.  Annu Rev Immunol. 2004;  22 531-562
• 66 Manderson A P, Botto M, Walport M J. The role of complement in the development of systemic lupus erythematosus.  Annu Rev Immunol. 2004;  22 431-456
• 67 Gough S CL, Walker L SK, Sansom D M. CTLA4 gene polymorphism and autoimmunity.  Immunol Rev. 2005;  204 102-115
• 68 Anderton S M. Post-translational modifications of self antigens-implications for autoimmunity.  Curr Opin Immunol. 2004;  16 753-758
• 69 Amano K, Leung P SC, Rieger R et al.. Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid.  J Immunol. 2005;  174 5874-5883
• 70 Sercarz E E, Lehmann P V, Ametani A, Benichou G. Dominance and crypticity of T cell antigenic determinants.  Annu Rev Immunol. 1993;  11 729-766
• 71 Rosen A, Casciola-Rosen L. Autoantigens as substrates for apoptotic proteases: Implications for the pathogenesis of systemic autoimmune disease.  Cell Death Differ. 1999;  6 6-12